Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Benchmarking of DDA and plexDIA analysis with SILAC-labelled Hela cell samples

ABSTRACT: SILAC labelled Hela cell lysates were mixed in defined ratios and analysed using both DDA and DIA methods, to serve as a benchmark for the novel plexDIA features of DIA-NN.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell, Hela Cell

DISEASE(S): Cervix Carcinoma

SUBMITTER: Toman Bortecen

LAB HEAD: Jeroen Krijgsveld

PROVIDER: PXD039580 | Pride | 2023-10-19

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20220603_QE1_TB_A3R1_DDA1.raw	Raw
	20220603_QE1_TB_A3R1_DDA2.raw	Raw
	20220603_QE1_TB_A3R1_DDA3.raw	Raw
	20220603_QE1_TB_A3R2_DDA1.raw	Raw
	20220603_QE1_TB_A3R2_DDA2.raw	Raw

Items per page:

1 - 5 of 12

Similar Datasets

Benchmarking plexDIA analysis with SILAC-labelled Hela cell samples

Project description:SILAC labelled Hela cell lysates were mixed in defined ratios and analysed using both DDA and DIA methods, to serve as a benchmark for the novel plexDIA features of DIA-NN.

2023-10-19 | PXD039578 | Pride

Proteomic analysis of GC7-treated senescent and proliferating BJ fibroblasts

Project description:Quantitative analysis of global proteomic changes in proliferating and senescent BJ fibroblasts, treated with eIF5A hypusination inhibitor GC7 (10 uM) for 12h.

2024-07-12 | PXD034251 | Pride

semi-automated enrichment of AHA-containing newly-synthesized proteins with magnetic alkyne agarose beads

Project description:Development of an improved workflow for newly synthesized proteome analysis, based on combined pulsed metabolic labelling with L-azidohomoalanine (AHA) and semi-automated click chemistry-based enrichments with magnetic alkyne agarose beads.

2023-10-19 | PXD036886 | Pride

Nascent proteome analysis of proliferating and senescent BJ fibroblast treated with GC7

Project description:Analysis of proteomic changes in proliferating and senescent BJ fibroblast treated with eIF5A hypusination inhibitor GC7 for 12h.

2024-07-12 | PXD034334 | Pride

Applying plexDIA analysis to newly synthesized proteome samples generated using a semi-automated enrichment protocol

Project description:Samples generated with a newly development semi-automated enrichment protocol for newly synthesized proteins, using different amounts of protein input, were analysed using data-independent acquisition (DIA) and processed with the plexDIA software features of DIA-NN (https://www.nature.com/articles/s41587-022-01389-w).

2023-10-19 | PXD043817 | Pride

Newly synthesized proteome analysis of interferon gamma treated Hela cells

Project description:Using a newly-developed workflow for quantitative newly synthesized proteome analysis (QuaNPA), featuring automated sample processing and multiplexed DIA (plexDIA) analysis, changes in the newly synthesized proteome of IFN-gamma treated Hela cells were monitored over time.

2023-10-19 | PXD038915 | Pride

DIA-MS analysis of 24 breast cancer tissues

Project description:In recent years genomic and proteomic technologies have been employed in a combined effort to extrapolate key clinical and biological information of complex diseases such as cancer. Most integrative studies employ DNA and/or RNA sequencing technologies coupled to mass spectrometry-derived information to achieve deep information extraction levels, resulting in massive experimental efforts. In this context the employment of data independent acquisition (DIA) methods, which generally do not rely on fractionation, has seldom been tested. In this study, we evaluated the ability of DIA and data dependent acquisition (DDA) MS in determining key biological features of a set of 21 breast cancer tissues for whose RNA-sequencing data was also collected. We evaluated how proteomic data layers matched RNA analysis-derived genomic information, their degree of consensus, and their discrepancies.

2021-04-26 | PXD021394 | Pride

DIA-MS analysis of 21 breast cancer tissues

2021-04-26 | PXD018830 | Pride

Harnessing PROTAC technology to combat stress hormone receptor activation

Project description:We want to quantify the proteome alteration following PROTAC mediated Glucocorticoid receptor depletion in vitro.

2023-12-11 | PXD046949 | Pride

Considerations for peptide and protein error rate control in large-scale targeted DIA analyses: plasma analysis

Project description:Liquid chromatography coupled to tandem mass spectrometry has become the main method for high-throughput identification and quantification of peptides and the inferred proteins. Discovery proteomics commonly employs data-dependent acquisition in combination with spectrum-centric analysis. The accumulation of data generated from thousands of samples by this method has approached saturation coverage of different proteomes. Recently, as a result of technological advances, methods based on data acquisition strategies compatible with peptide-centric scoring have also reached similar proteome coverage in individual runs, and scalability. This is exemplified by SWATH-MS, which combines data-independent acquisition (DIA) with targeted data extraction of groups of transitions uniquely detecting a peptide. As the data matrices generated by these experiments continue to grow with respect to both the number of peptides identified per sample and the number of samples analyzed per study, challenges for error rate control have emerged. Here, we discuss the adaptation of statistical concepts developed for discovery proteomics based on spectrum-centric scoring to large-scale DIA experiments analyzed with peptide-centric scoring strategies, and provide some guidance on their application. We propose that, in order to increase the quality and reproducibility of published proteomic results, well-established confidence criteria should be reported at each level as we progress from spectral evidence to identified or detected peptides and inferred proteins. These confidence criteria should equally be applied to proteomic analyses based on spectrum- and peptide-centric scoring strategies.

2017-08-03 | PXD006625 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data